These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 17289397)

  • 1. Tolerability of statins is not linked to CYP450 polymorphisms, but reduced CYP2D6 metabolism improves cholesteraemic response to simvastatin and fluvastatin.
    Zuccaro P; Mombelli G; Calabresi L; Baldassarre D; Palmi I; Sirtori CR
    Pharmacol Res; 2007 Apr; 55(4):310-7. PubMed ID: 17289397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of thyroid hormone status and concomitant medication on statin induced adverse effects in hyperlipidemic patients.
    Berta E; Harangi M; Zsíros N; Nagy EV; Paragh G; Bodor M
    Pharmazie; 2014 Jun; 69(6):420-3. PubMed ID: 24974574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.
    Alvarez-Sala LA; Cachofeiro V; Masana L; Suarez C; Pinilla B; Plana N; Trias F; Moreno MA; Gambus G; Lahera V; Pintó X
    Clin Ther; 2008 Jan; 30(1):84-97. PubMed ID: 18343245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of potentially severe drug-drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy.
    Rätz Bravo AE; Tchambaz L; Krähenbühl-Melcher A; Hess L; Schlienger RG; Krähenbühl S
    Drug Saf; 2005; 28(3):263-75. PubMed ID: 15733030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Statin myopathy: a lipid clinic experience on the tolerability of statin rechallenge.
    Fung EC; Crook MA
    Cardiovasc Ther; 2012 Oct; 30(5):e212-8. PubMed ID: 21884002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers.
    Kirchheiner J; Kudlicz D; Meisel C; Bauer S; Meineke I; Roots I; Brockmöller J
    Clin Pharmacol Ther; 2003 Aug; 74(2):186-94. PubMed ID: 12891229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence of skeletal muscle disorders after statins' treatment: consequences in clinical and EMG picture.
    Drobny M; Pullmann R; Odalos I; Skerenova M; Saniova B
    Neuro Endocrinol Lett; 2014; 35(2):123-8. PubMed ID: 24878976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simvastatin-induced myopathy, the role of interaction with diltiazem and genetic predisposition.
    Hu M; Mak VW; Tomlinson B
    J Clin Pharm Ther; 2011 Jun; 36(3):419-25. PubMed ID: 21545622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug-drug interactions that interfere with statin metabolism.
    Hirota T; Ieiri I
    Expert Opin Drug Metab Toxicol; 2015; 11(9):1435-47. PubMed ID: 26058399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Statin therapy and muscle disorders].
    Abel T; Fehér J
    Orv Hetil; 2009 Feb; 150(6):261-3. PubMed ID: 19179258
    [No Abstract]   [Full Text] [Related]  

  • 12. No effect of CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) on lipid-lowering response to statins in Greek patients with primary hypercholesterolemia.
    Ragia G; Kolovou V; Tavridou A; Elens L; Tselepis AD; Elisaf M; Van Schaik RH; Kolovou G; Manolopoulos VG
    Drug Metab Pers Ther; 2015 Mar; 30(1):43-8. PubMed ID: 25274942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and tolerability of fluvastatin XL 80 mg alone, ezetimibe alone, and the combination of fluvastatin XL 80 mg with ezetimibe in patients with a history of muscle-related side effects with other statins.
    Stein EA; Ballantyne CM; Windler E; Sirnes PA; Sussekov A; Yigit Z; Seper C; Gimpelewicz CR
    Am J Cardiol; 2008 Feb; 101(4):490-6. PubMed ID: 18312764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin.
    Brunham LR; Lansberg PJ; Zhang L; Miao F; Carter C; Hovingh GK; Visscher H; Jukema JW; Stalenhoef AF; Ross CJ; Carleton BC; Kastelein JJ; Hayden MR
    Pharmacogenomics J; 2012 Jun; 12(3):233-7. PubMed ID: 21243006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipid-lowering effect of fluvastatin in relation to cytochrome P450 2C9 variant alleles frequently distributed in the Czech population.
    Buzková H; Pechandová K; Danzig V; Vareka T; Perlik F; Zak A; Slanar O
    Med Sci Monit; 2012 Aug; 18(8):CR512-517. PubMed ID: 22847201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic polymorphisms in cytochrome P450 enzymes: effect on efficacy and tolerability of HMG-CoA reductase inhibitors.
    Vermes A; Vermes I
    Am J Cardiovasc Drugs; 2004; 4(4):247-55. PubMed ID: 15285699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of once-daily vs twice-daily dosing with fluvastatin, a synthetic reductase inhibitor, in primary hypercholesterolemia.
    Insull W; Black D; Dujovne C; Hosking JD; Hunninghake D; Keilson L; Knopp R; McKenney J; Stein E; Troendle AJ
    Arch Intern Med; 1994 Nov; 154(21):2449-55. PubMed ID: 7979841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CYP2D6*4 polymorphism is associated with statin-induced muscle effects.
    Frudakis TN; Thomas MJ; Ginjupalli SN; Handelin B; Gabriel R; Gomez HJ
    Pharmacogenet Genomics; 2007 Sep; 17(9):695-707. PubMed ID: 17700359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic cough as a complication of treatment with statins: a case report.
    Psaila M; Fsadni P; Montefort S
    Ther Adv Respir Dis; 2012 Aug; 6(4):243-6. PubMed ID: 22761129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk identification and possible countermeasures for muscle adverse effects during statin therapy.
    Magni P; Macchi C; Morlotti B; Sirtori CR; Ruscica M
    Eur J Intern Med; 2015 Mar; 26(2):82-8. PubMed ID: 25640999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.